We conducted a controlled multicenter trial with central randomization and evaluation of events under blind conditions involving 652 patients with unstable angina. Patients were treated either with conventional therapy alone (group C) (n =338) or with conventional therapy combined with an inhibitor of platelet aggregation, ticlopidine 250 mg b.i.d. (group C+T) (n=314). Patients were assigned randomly within 48 hours of admission and followed up for 6 months. With the "intention-to-treat" approach, the primary end points, vascular death and nonfatal myocardial infarction, were observed in 13.6% of the patients in group C and in 7.3% of the patients in group C+T, which is a reduction in risk of 46.3% (p=0.009). Vascular mortality was 4.7% in patients in group C and 2.5% in patients in group C+T, which is a reduction in risk of 46.8% (p=0.139). The risk of nonfatal myocardial infarction was reduced by 46.1% (p=0.039), with a frequency of 8.9o in patients in group C and 4.8% in patients in group C+T. New Q wave myocardial infarction occurred with a frequency of 6.8% in patients in group C and 3.8% in patients in group C+T, which is a reduction in risk of 44.1% (p=0.091). Fatal and nonfatal myocardial infarction was 10.91% in patients in group C and 5.1% in patients in group C+T, which is a reduction in risk of 53.2% (p=0.006). These findings confirm the importance of platelets in the pathogenesis of unstable angina and the usefulness of antiplatelet treatment for the prevention of cardiovascular events.
angina in Italy in 1986, when the protocol was designed. Nowadays, aspirin is more widely used.
Methods

Study Design
The study was planned as a completely random multicenter trial with central randomization and treatment allocation balanced within centers. About one quarter of the Italian coronary care units (CCU) were involved. For this reason, the study was organized as a pragmatic trial17 to reproduce as closely as possible current clinical practice with an easyto-follow protocol and uncomplicated patient monitoring. The effectiveness of treatment was assessed by qualitative evaluation of selected primary end points (described herein), with validation of endpoint occurrences under blind conditions by an independent validation committee.
Patients
Enrollment of patients started December 1, 1986 , and closed October 30, 1987 . During this time, all male and female patients not more than 75 years old who presented with symptoms suggesting unstable angina were recruited consecutively within 48 hours after admission to the CCU.
Unstable angina was defined as follows: 1) new onset or sudden worsening of effort angina without increased physical activity during the last month, 2) new onset or worsening (less than 1 month earlier) of angina at rest, still present in the week before admission (at least five episodes), with at least one episode lasting longer than 15 minutes, or 3) angina attacks at rest, at least one of which lasted more than 15 minutes in the 12 hours before admission.
While in the hospital and before randomization, the patients had to show transient depression of the ST segment (21 mm horizontally or downsloping for 80 msec from the J-point), ischemic inversion of the T wave recorded during angina episodes or in the hours immediately thereafter without elevation of enzyme levels, or both.
Effort tests could be given to patients with the previously mentioned second type of unstable angina to confirm the diagnosis. The criteria for exclusion are listed in Table 1 .
Organization
At admission, all patients were given the conventional treatment used at each CCU (i.e., /3-blockers, calcium antagonists, and nitrates). Within 48 hours after hospitalization, the initials, sex, age, and date of admission for patients who fulfilled the inclusion criteria were transmitted by telephone to the Data Management Center, which then announced which treatment was randomly assigned, that is, either to continue the conventional therapy alone (group C) or to add ticlopidine 250 mg b.i.d. to conventional therapy (group C+T). The Data Management Center used the data previously mentioned to ensure that each patient was correctly identified in case-record form. Each CCU was to record in a log all consecutively screened patients and to check inclusion/ exclusion criteria.
Once discharged, patients continued their randomly assigned treatments and had clinical checkups 1, 2, 3, and 6 months after enrollment. At each checkup, there was a clinical examination and the electrocardiogram (ECG) was monitored. Blood for studies of cardiac enzymes was taken only if the clinical picture or ECG had changed. Blood counts were performed at each checkup. The patient was queried about his or her consumption of pills and reminded to not take any of the drugs listed in the explanatory pamphlet given when leaving the hospital. No other drugs that can affect platelet function or blood coagulation could be taken during the 6 months of the trial.
If a primary or secondary event occurred (as herein defined), a special form was completed. This form was sent, with all the documentation required to describe the event but without treatment information, in a sealed envelope to the independent validation committee for evaluation of the clinical outcome under blind conditions. According to Italian law, the protocol was approved by the Ethical Review Committee of each Center. All patients agreed to undergo the study procedures.
The Data Management Center was advised on special forms of any adverse reactions or withdrawals and the occurrence of events by the independent validation committee.
End Points
The Primary end points. Event-free analysis of the trial time of each patient was performed by the log-rank test.2223 The survival curve was estimated by means of the Kaplan-Meier technique.24 "Trial time" means the time during which a patient took part in the trial, measured in days from the time of assignment to the appearance of an event, or from the time of assignment to the end of the trial for patients who presented no events.
Secondary end points. The occurrence of these events was only described and was not included in the statistical evaluation.
In accordance with the protocol, intention-to-treat analysis was conducted by evaluating all the enrolled patients, and a second analysis evaluated all patients who completed the protocol without violations and were therefore judged "eligible." 
Results
Patient Screening
After stopping the recruitment, all centers except four that had recruited only a total of 28 patients sent in their logs. A total of 2,438 patients with suspected unstable angina had been screened, of whom 1,814 (74.4%) had been excluded (Table 1) , and the remaining 624 (25.6%) were assigned randomly. The total number of recruited patients became 652 after the addition of the 28 patients from the four centers previously mentioned.
Group Characteristics
The two groups of patients were homogeneous for all the variables considered ( Group C, conventional therapy; Group C+T, conventional therapy plus ticlopidine. CRF, coronary risk factor; HHD, history of heart disease factor; MI, myocardial infarction.
*Total frequencies exceed the patient number because some of them had more than one CRF or HHD. (Table 3 ); 8.3% of the patients in group C and 8.0% of the patients in group C+T left the trial because they had aortocoronary bypasses or balloon angioplasties. Fifteen patients in group C+T discontinued treatment because of adverse reactions to ticlopidine. Eight patients in group C (2.4%) and two in group C+T (0.6%) withdrew because of severe angina attacks requiring therapy not compatible with the protocol.
We did not consider the need to perform bypass surgery or angioplasty as secondary end points, not only because these procedures were performed because of physician judgment, but also because it was not equally possible to resort to these procedures at all centers. Side Effects
In group C+T, 15 adverse gastrointestinal reactions to ticlopidine were observed (i.e., diarrhea, nausea, vomiting, and epigastric pain), 10 of them requiring discontinuation of ticlopidine. There were also six skin reactions, five of them requiring discontinuation, and four mild bleeding disorders (i.e., epistaxis, gingival bleeding, and ecchymoses) that recovered without discontinuation. In group C, 13 central and peripheral nervous system disorders (e.g., headache and vertigo) were observed, seven of them requiring changes in therapy. Three gastrointestinal disorders (one therapy change) and 11 peripheral edemas (six therapy changes) were reported. The 14 patients in group C with side effects to conventional therapeutic agents requiring discontinuation of therapy changed treatment without leaving the study.
Blood cell counts never showed abnormalities of clinical importance.
Protocol Adherence
A total of 55 patients were not considered eligible by the independent validation committee after recruitment and before event validation because of substantial deviations from the protocol (in only three centers). These included nonconsecutive enrollment or enrollment outside the CCU (20 patients per group), or concomitant anticoagulant therapy after randomization (eight in group C and seven in group C+T). Of the 597 eligible patients, 309 were treated with conventional therapy and 288 with conventional therapy plus ticlopidine. The two groups were still homogeneous for all the descriptive variables considered after a further statistical evaluation.
Compliance with the assigned treatment was assessed by interviews with the patients.
End Points
Intention-to-treat analysis ( The time distribution of the primary end points is shown in Table 5 . Event-free survival analysis was performed for all the randomized patients as well as for the eligible patients, and the cumulative probability of developing primary events for both treatment groups is given in Figure 1 . nonfatal strokes and two peripheral occlusive arteriopathies; all of them occurred in patients in group C. Discussion The present trial confirms that the clinical course of patients with unstable angina can be improved by treatment with antiplatelet drugs, as seen in the clearcut reduction of cardiovascular events in the group of patients receiving ticlopidine, in which MI and vascular death were decreased by 46.3% (p=0.009). These effects of a drug that inhibits platelet function by a mechanism different from that of aspirin are further indications that platelets play a pivotal role in the pathogenesis of cardiovascular complications of unstable angina.
Ticlopidine: Mode ofAction and Clinical Use
Ticlopidine is a thienopyridine derivative that inhibits platelet function in experimental models and in humans. Its inhibitory effects on platelet aggregation in humans appear 24-48 hours after administration of 500 mg/day. This suggests that the antiaggregation effect might be due to active metabolites. 26 The mechanism by which ticlopidine inhibits platelet aggregation is completely different from the mechanism of aspirin because it does not have any effects on cyclooxygenase.27 Recent studies indicate that ticlopidine inhibits ADP-mediated platelet aggregation15 and antagonizes the interaction of fibrogen with its platelet receptor, the membrane glycoprotein IIb-IIIa. 16 Ticlopidine has been given to patients with several clinical forms of atherosclerosis, such as transient ischemic attack, stroke, and peripheral vascular disease. In patients who have had stroke, ticlopidine decreased the incidence of such later vascular accidents as stroke, myocardial infarction, and vascular death by 23.3%.28 Ticlopidine was also effective in patients with peripheral vascular disease in a randomized, double-blind placebo-controlled study with a duration of 21 months. The patients treated with ticlopidine had significant improvement in walking distance and slower worsening of peripheral blood flow. 29 In the same type of patient, it was also found possible to decrease the cardiovascular complications that usually complicate their clinical course.3031 Finally, in a recent study, the ability of aspirin and ticlopidine to prevent cardiovascular complications in patients with transient ischemic attack were compared. The patients treated with ticlopidine had a lower frequency of stroke. 32 Ticlopidine has never been studied in patients with ischemic heart disease except for one study evaluating its ability to prevent occlusion of aortocoronary bypasses. Ticlopidine was significantly better than placebo for decreasing occlusion of the bypass graft.33
Platelets and Unstable Angina
There is considerable evidence suggesting that platelet activation and formation of thrombi in coronary vessels are the bases for unstable angina.
Angiographic34 and autopsy35 studies of select patient populations and, even more, the positive results with aspirin in the clinical trials of Lewis et al"l and Cairns et al, 13 and of ticlopidine in our trial, tend to confirm this hypothesis. Additionally, a recent study by Theroux et 
Conclusion and Implications
Coronary thrombosis, which is recognized as the main cause of myocardial infarction,39 seems to be the most important factor in the early evolution of unstable angina. The data of Lewis et all' and Theroux et a136 and our own data clearly demonstrate that myocardial infarction is the most frequent event complicating the early phase of unstable angina and that antiplatelet therapy can reduce it. Thus, prevention of myocardial infarction seems to be the main goal of antiplatelet therapy during the acute phase (initial 3 months) of unstable angina. In a previous study, aspirin appeared to be less effective for cerebrovascular disease in women than in men,40 whereas while investigating the benefits of aspirin for patients with unstable angina, Cairns et a113 found it effective even in women. Our study shows that the antiplatelet therapy with ticlopidine is equally effective in both sexes.
Finally, the efficacy of ticlopidine treatment seemed to have been greater in patients with unstable angina who also had a history of MI. This might indicate an additional prophylactic use of this drug after infarction, which is a much less sensitive model than unstable angina, because the decreased rates of events in previous studies were not always unequivocal. [3] [4] [5] [6] [7] [8] [9] [10] 41 All of these data indicate that giving antiaggregating agents to patients with unstable angina helps in the prophylaxis of cardiovascular events. This type of treatment should decrease the cost and the risks inherent with the usual surgical treatment of a disease that affects at least 25% of patients admitted to cardiovascular units with diagnoses of suspected unstable angina. Our results indicate that ticlopidine might well be a valid alternative to aspirin.
